Interestingly, mounting evidence from clinical studies suggests that this PPAR agonist prevents the ARDS/ALI in COVID-19 patients by downregulating NF-κB and JAK/STAT signaling and then reducing TNF-α, IL1β, and IL6 levels. The gene discussed is NFKB1; the disease is acute respiratory distress syndrome.